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Introduction 
 
Nonalcoholic fatty liver disease (NAFLD) is the 
most frequent cause of liver damage and the 
most common reason for abnormal hepatic en-
zymes worldwide [1-4]. NAFLD is characterized 
by fat accumulation in the liver that starts with 
simple hepatic steatosis and may progress to-
ward inflammation (nonalcoholic steatohepatitis 
[NASH]) with progressive fibrosis [4-6]. Major 
advances have been made in understanding the 
pathogenesis of NAFLD but the mechanisms 
that lead from benign steatosis to NASH are still 
poorly understood. 
 
NAFLD is strongly associated with the metabolic 
syndrome and its defining pathophysiological 
components obesity, diabetes and dislipidemia. 
Thus, overeating delivers an excess of triglyc-
erides to the liver. Further, peripheral lipolysis in 
obese and insulin resistant states leads to an 
increased hepatic influx of fatty acids (FA). In 
addition, hepatic FA synthesis is increased sec-
ondary to elevated glucose and insulin levels. 
Together, both uptake of exogenously derived 
FA and de novo hepatic synthesis of FA lead to 
an increase of hepatic lipid content, e.g. hepatic 
steatosis [3,7,8]. 
 
Fatty acid synthase (FASN) catalyzes the last 
step in fatty acid biosynthesis, and thus, it is 
believed to be a major determinant of the maxi-
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mal hepatic capacity to generate FA by de novo 
lipogenesis. FASN synthesizes long chain FAs by 
using acetyl-CoA as a primer, malonyl-CoA as a 
carbon donor, and NADPH as a reducing equiva-
lent [9-11]. Thus under normal conditions, ex-
cess carbohydrates are converted into FA, fol-
lowed by esterification to triacylglycerols, which 
when necessary, provide energy through beta-
oxidation. 
 
In NAFLD increased mitochondrial oxidation of 
FA takes place as a compensatory adaptation. 
However, this homeostatic response leads to 
increased mitochondrial reactive oxygen prod-
ucts (ROS), and in a chronic stage, results in 
lipid peroxidation, inflammation and fibrogene-
sis [7,12,13]. 
 
Sterol regulatory element-binding proteins 
(SREBPs) are the major transcriptional factors 
in lipogenic gene expression including FASN 
[14]. SREBP1 is induced by high insulin levels, 
and feeding a high carbohydrate diet rapidly 
induced hepatic FASN expression in rats [15]. 
Furthermore, SREBP1 mRNA expression levels 
have been found to be increased in animal 
models of NASH [16]. However, information 
regarding FASN expression and function in 
NAFLD is sparse and studies in man are almost 
exclusively based on mRNA expression analysis 
and small patient numbers. 
 
The aim of this study was to analyze FASN pro-
tein expression in a large number of patients 
with normal liver histology or NAFLD without or 
with hepatic inflammation (e.g. NASH). In addi-
tion, SREBP1 and FASN expression were investi-
gated in experimental murine models of nonal-
coholic hepatic steatosis or steatohepatitis, and 
in an in vitro model of lipid accumulation in pri-
mary human hepatocytes.  
 
Materials and methods 
 
Chemicals and reagents 
 
Palmitic acid (Cat#P0500) and recombinant 
human tumor necrosis factor alpha (TNF) 
(Cat#T0157) were obtained from Sigma phar-
maceuticals (Hamburg, Germany). 
 
Intracellular triglyceride assay 
 
Total triglycerides were extracted using the 
method of Bligh and Dyer with slight modifica-
tions [17,18] and quantified with the GPO-
triglyceride kit (Sigma, Deisenhofen, Germany) 
as described [19]. 
 
Murine models of hepatic steatosis and hepatic 
inflammation 
 
Male BALB/c mice were purchased from 
Charles River Laboratories (Sulzfeld, Germany) 
at 6 weeks of age and housed in a 22°C con-
trolled room under a 12 h light-dark cycle with 
free access to food and water. After 1 week of 
acclimatization mice were divided into three 
groups (n=6 each) and fed either with control 
diet, a high fat diet (HFD) containing 30% lard or 
a NASH inducing diet containing 30% lard, 
1.25% cholesterol and 0.5% sodium cholate 
[20]. All chows were prepared by Ssniff (Soest, 
Germany). After 12 weeks feeding animals were 
sacrificed. Liver tissue was immediately snap-
frozen and stored at -80°C for subsequent 
analysis.  
 
Bile duct ligation (BDL) or sham operations were 
performed as described [21]. 
 
Human cell, tissues and tissue microarray 
(TMA) 
 
Primary human hepatocytes (PHH) were isolated 
and cultured as described [23]. Formalin-fixed, 
paraffin-embedded human liver tissues for con-
struction of a tissue microarray (TMA) were re-
trieved from the surgical pathology files of the 
Institute of Pathology of the University of Re-
gensburg, covering a period of 11 years (1995 
to 2006). The following exclusion criteria were 
applied: 1. chronic alcohol abuse (more than 30 
g/day for men and 20g/day for women), 2. 
medications known to cause hepatic steatosis 
(at present or within the last 2 years), 3. signifi-
cant weight loss (more than 3 kg within the last 
3 months), 4. hepatobiliary diseases, 5. ascites 
in ultrasound, 6. inflammatory bowel disease, 7. 
infection with the human immunodeficiency 
virus or Hepatitis B and C virus, and 8. chemo-
therapy prior to partial hepatectomy. Thus, a 
TMA could be constructed with liver tissue from 
106 different patients as described [24]. All 
patients were of Caucasian origin, 50 (46.7%) 
were male, and had undergone partial hepatec-
tomy for metastatic liver tumors. The mean age 
was 60.8±12.0 years. 
 
In addition to formalin-fixed liver tissue for TMA 
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construction, 16 corresponding liver specimens, 
which had been immediately snap frozen after 
surgical resection and stored at -80°C, were 
available. 
 
Human liver tissue was obtained and experi-
mental procedures were performed according to 
the guidelines of the charitable state controlled 
foundation HTCR, with the informed patient's 
consent, and the study was approved by the 
local ethics committee of the University Regens-
burg. 
 
Histological NAFLD/NASH score 
 
A modified histological NAFLD/NASH Score ac-
cording to the recommendations of the Nonalco-
holic Steatohepatitis Clinical Research Network 
was used [25]. Briefly, four histological features 
were evaluated semi-quantitatively: steatosis (0-
3), lobular inflammation (0-2), hepatocellular 
ballooning (0-2), and fibrosis (0-4). Steatohepa-
titis was diagnosed when the sum of the scores 
was 4 or more. 
 
Immunohistochemical analysis  
 
Immunohistochemical staining of 5-µm sections 
of the tissue microarray (TMA) blocks was per-
formed using polyclonal anti-FASN antibody 
(Abnova (Taiwan), clone 3F2-1F3, dilution 
1:2,000) with an automated platform (Bond; 
Labvision, Fremont, CA, USA) as described previ-
ously [22]. A surgical pathologist (M.O.R.) per-
formed a blinded evaluation of the stained 
slides. For negative control, the primary anti-
body was omitted and IgG isotype control anti-
bodies did not reveal any detectable staining. 
Protein expression of FASN was evaluated semi-
quantitatively using a 2-tiered system for inten-
sity when at least 10% of hepatocytes were 
positive. Liver specimens were scored as weakly 
positive, when a faint cytoplasmatic signal using 
the 100x magnification was barely detectable. 
Hepatic tissues were scored as strongly positive 
when a dark brown staining was detected using 
a 100x magnification.  
 
Quantitative real time-PCR analysis 
 
Isolation of total cellular RNA from cultured cells 
and tissues and reverse transcription were per-
formed as described [26]. Quantitative real time
-PCR was performed applying LightCycler tech-
nology (Roche, Mannheim, Germany) as de-
scribed [27] applying the following pairs of prim-
ers: murine MCP-1 (forward: 5'‑TGGGCCTGCTGT 
TCACA; reverse: 5'‑TCCGATCCAGGTTTTTAAGTA). 
Expression of murine and human FASN, 
SREBP1 and TNF mRNA was analyzed with the 
QuantiTect Primer Assays according to the 
manufacturer's instructions (Qiagen, Hilden, 
Germany). 
 
Statistical analysis 
 
Statistical analyses were performed using SPSS 
version 10.0 (SPSS, Chicago, IL, USA) and 
GraphPad Prism Software (GraphPad Software, 
Inc., San Diego, USA). Results are expressed as 
mean ± standard error (range) or percent. Com-
parisons between groups were made using the 
Mann-Whitney test. Contingency table analysis 
and the two-sided Fisher’s exact test were used 
to study the statistical association between 
clinicopathological and immunohistochemical 
variables. P-values <0.05 were considered sta-
tistically significant. 
 
Results 
 
FASN expression in an in vitro model of      
hepatocellular lipid accumulation 
 
First, we analyzed FASN expression in an in vitro 
model of hepatocellular lipid accumulation, 
which we have recently described [19]. Incuba-
tion of primary human hepatocytes (PHH) with 
palmitic acid induced a dose dependent intra-
cellular triglyceride accumulation (Figure 1A), 
and notably, FASN mRNA expression (Figure 
1B). In contrast, stimulation of PHH with TNF did 
not significantly change FASN expression 
(Figure 1C). 
 
FASN expression in murine NAFLD models 
 
Next, we investigate hepatic FASN expression in 
two different murine NAFLD models. In one 
model, which closely resembles (histo)
pathophysiological changes observed in human 
NASH [20], mice received a high fat diet (30% 
lard) supplemented with cholesterol and cho-
late. In the second model, mice received a high 
fat diet with the identical lipid content as in the 
first model but without cholesterol and cholate. 
As it has been show before by others [20,28] 
and our group [29,30], twelve weeks feeding of 
both diets induced a significant and comparable 
steatosis in both groups (Figure 2A and data not 
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shown). However, in accordance with the litera-
ture [28-30], feeding of high fat only does not 
induce significant hepatic inflammation, while 
the additional application of cholesterol and 
cholate lead to manifest hepatic inflammation, 
as evidenced by increased expression of the 
proinflammatory cytokines tumor necrosis fac-
tor (TNF) and monocyte chemotactic protein-1 
(MCP-1) (Figure 2B), both known to play an im-
portant role in development and progression of 
Figure 1. FASN expression in an in vitro model of hepatocellular lipid accumulation. Primary human hepatocytes were 
incubated with 0.2 mM and 0.4 mM palmitate (Palm.) or TNF (10 ng/ml) for 24 h. (A) Colorimetric assessment of 
intracellular triglyceride content. (B,C) Analysis of FASN mRNA expression by quantitative PCR. (*p<0.05 compared to 
control (ctr.)). 
Figure 2. Hepatic FASN expression in two murine models of NAFLD and in a model of hepatic injury and inflammation 
not related to NAFLD. Mice were fed either a high fat diet leading to hepatic steatosis or a NASH inducing diet for 12 
weeks. Mice receiving standard chow served as control (ctr.). In a second experimental setting mice underwent bile 
duct ligated (BDL) for 3 weeks to induce liver injury and hepatic inflammation (without steatosis). Sham-operated 
mice served as control (sham). (A) HE-staining of liver tissue sections from mice fed either high fat (II), NASH inducing 
(III) or control diet (I). (magnification 100X)  (B,C) Analysis of hepatic FASN, TNF and MCP-1 mRNA expression by 
quantitative PCR. (*p<0.05 compared to control). 
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hepatic inflammation. Of note, FASN expression 
was significantly increased in mice with hepatic 
steatosis without inflammation but not in NASH 
as compared to control mice (Figure 2B). 
 
Furthermore, we analyzed FASN in a third mur-
ine model of liver damage, the bile-duct ligation 
(BDL) model, which is not related to NAFLD. This 
model is characterized by severe hepatocellular 
damage and inflammation, and while we ob-
served markedly elevated expression of proin-
flammatory genes, hepatic FASN expression 
levels did not differ from those in sham oper-
ated control mice (Figure 2C). 
 
FASN expression in patients with and without 
NAFLD 
 
To study FASN expression in a large number of 
NAFLD patients in comparison to individuals 
with normal liver histology, we performed FASN 
immunohistochemical staining of a TMA com-
prising 106 non-tumorous hepatic tissue speci-
mens with different degree of steatosis and 
inflammation. Exclusion criteria ruled out alco-
holic steatohepatitis, and hepatic steatosis sec-
ondary to medication, rapid weight loss or infec-
tion with hepatitis C virus. Immunohistochemi-
cal staining was informative in 102 cases, and 
revealed a homogenous cytoplasmatic staining 
pattern of hepatocytes in all patients (Figure 
3A). However, the intensity of the immunohisto-
chemical FASN signal revealed significant differ-
ences in individual patients, and thus, was sys-
tematically categorized into weak or strong 
staining. Representative examples of weak and 
strong staining intensity are depicted in Figure 
3A. 
Figure 3. FASN expression in liver tissues of patients with and without NAFLD. (A) FASN immunohistochemical stain-
ing of a tissue micro array comprising 106 non-tumorous hepatic tissue specimens with different degree of steatosis 
and inflammation. Representative pictures of a (I) healthy liver, weakly positive for FASN (arrow: the coarse brown 
material is lipofuscin), (II) steatotic liver without inflammation showing strong cytoplasmatic positivity for FASN, and 
(III) NASH liver, weakly positive for FASN (bold arrow: lobular inflammation; thin arrow: the coarse brown material is 
lipofuscin). Magnification 200X and 400X in the insert, respectively. (B) Comparison of FASN mRNA expression levels 
in liver samples with high or low FASN protein expression as assessed by semiquantitative evaluation of FASN immu-
nohistochemistry (IH). (C) Analysis of FASN mRNA expression levels in normal (ctr.), steatotic and NASH human liver 
tissues by quantitative PCR. (*p<0.05 compared to control). 
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Interestingly, the intensity of the FASN immuno-
reactivity correlated significantly with the degree 
of hepatic steatosis, while no association was 
found with hepatic inflammation or ballooning 
of hepatocytes (Table 1). Also, FASN staining 
intensity showed no correlation with age, gen-
der, degree of obesity or presence of diabetes. 
 
Matched frozen hepatic tissue samples for 
mRNA analysis and semiquantitative assess-
ment of protein expression on the TMA were 
available from 16 patients. FASN mRNA expres-
sion was significantly higher in cases with 
strong FASN immunosignal (n=3) compared to 
cases, where FASN signal was weak (n=16; Fig-
ure 3B). This finding confirmed that FASN ex-
pression was accurately detected by immuno-
histochemistry and that the categorization into 
samples with low or high FASN immunosignal 
truly reflected the hepatic FASN expression lev-
els.  
 
Also in line with the immunohistochemical stain-
ing results, FASN mRNA expression was signifi-
cantly higher in steatotic livers than in normal 
liver tissue (Figure 3C). Interestingly, FASN 
mRNA levels were slightly lower in NASH com-
pared to steatotic livers without inflammation.  
 
Regulation of FASN expression in nonalcoholic 
hepatic steatosis and steatohepatitis  
 
To get insight into the regulation of FASN ex-
pression in NAFLD, we investigated SREBP1, a 
known transcriptional regulator of FASN, in the 
in vitro model of hepatocellular lipid accumula-
tion described above. Lipid accumulation in pri-
mary humane hepatocytes significantly induced 
SREBP1 expression (Figure 4A), while stimula-
tion with TNF exhibited only a minimal effect on 
SREBP1 expression levels (Figure 4B). 
 
Similarly as in hepatocytes in vitro and in line 
with FASN expression levels, SREBP1 expres-
sion was significantly increased in steatotic 
murine and human livers without inflammation 
compared in normal hepatic tissue (Figure 4C, 
D). In contrast, FASN mRNA levels were slightly 
lower in NASH and did not differ from control 
tissue. 
 
Discussion 
 
The aim of this study was to analyze the expres-
sion of FASN, which is a central enzyme of he-
patic lipogenesis, in NAFLD. We revealed a sig-
nificant correlation of FASN expression with the 
degree of steatosis in primary human hepato-
cytes in vitro, as well as in experimental murine 
models and in livers of patients with NAFLD in 
vivo. Surprisingly, this association was only 
found in steatotic hepatic tissue without signifi-
cant inflammation, while FASN expression in 
murine and human NASH did not differ signifi-
cantly from levels in normal liver tissue. Similar 
data have been obtained by Ito et al. based on a 
Figure 4. SREBP1 expression in in vitro and in vivo models of hepatic steatosis and human NAFLD tissue. 
Analysis of SREBP1 mRNA expression by quantitative PCR in (A) Primary human hepatocytes (PHH) incubated with 
0.2 mM or 0.4 mM palmitate (Palm.) for 24 h, (B) PHH stimulated with TNF (10 ng/ml) for 24 h, (C) murine liver tis-
sues from control mice (ctr.), mice fed a high fat diet leading to hepatic steatosis and mice fed a NASH inducing diet, 
and (D) liver tissue from patients with healthy livers (ctr.), steatosis without inflammation or NASH. (*p<0.05 com-
pared to control (ctr.)). 
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different NASH model [31], and Mitsuyoshi et al. 
who found increased FASN mRNA expression in 
human steatotic liver tissue without histological 
signs of inflammation [32]. Noteworthy, we 
demonstrated that the expression levels of 
SREBP1, the main transcriptional regulator of 
FASN, paralleled the FASN mRNA expression 
levels in vitro and in vivo, and FASN mRNA and 
protein expression in human liver samples 
showed a significant correlation. 
These findings suggested that the increased 
FASN expression upon hepatocellular lipid accu-
mulation is regulated on the transcriptional 
level, while the observed steatosis induced in-
duction seems to be impaired by hepatic inflam-
mation. However, neither in vitro in primary hu-
man hepatocytes stimulated with TNF nor in 
vivo in an experimental model of liver inflamma-
tion, which is not related to NAFLD, FASN ex-
pression differed from control cells and tissues. 
Table 1. FASN immunoreactivity (IR) in liver tissue of 102 NAFLD patients and controls in relation to    
clinicopathological characteristics 
* Fisher's exact test (2-sided); bold face representing P-value <0.05. 
** class 0: <25 kg/m²; class 1: ≥25.0 and ≤29.9 kg/m²; class 2: >29.9 and ≤34.9 kg/m²; class 3 ≥35.0 kg/m² 
Variable         FASN IR P*   
  Categorization n %   weak strong   
                  
Age at diagnosis           0.810   
  <60 years 48 47.1   37 11     
  ≥60 years 54 52.9   44 10     
                  
Gender             1.000   
  female 56 54.9   44 12     
  male 46 45.1   37 9     
                
BMI class **               
  0 34 33.3   30 4 0.231   
  1 43 42.2   34 9     
  2 22 21.6   15 7     
  3 3 2.9   2 1     
                
steatosis           0.038   
  <5% 52 51.0   42 10     
  5-33% 40 39.2   34 6     
  34-66% 8 7.8   3 5     
  67-100% 2 2.0   2 0     
                
inflammation           0.169   
  none 85 83.3   70 15     
  mild 7 6.9   5 2     
  middle 6 6.9   4 2     
  strong 4 3.9   2 2     
                  
Ballooning             0.094   
  none 88 86.3   72 16     
  rare 11 10.8   8 3     
  frequent 3 2.9   1 2     
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In line with this, hepatic FASN expression in pa-
tients with NAFLD revealed no correlation with 
histological inflammation or ballooning of hepa-
tocytes as characteristic sign of advanced hepa-
tocellular damage. 
 
Thus, it appears that (hepatic) inflammation 
does not directly impair the increased FASN 
expression in response to hepatocellular lipid 
accumulation. Rather, one may speculate 
whether a lack of FASN increase in NAFLD actu-
ally predisposes to hepatic inflammation. Actu-
ally, while mice with liver specific FASN knock 
out reveal a similar phenotype as control mice 
when fed a control diet, they developed hepatic 
steatosis due to reduction of beta-oxidation 
upon feeding a low fat high carbohydrate diet 
[33]. Although such a feeding model is not di-
rectly related to the situation found in most pa-
tients with NAFLD, it appears that - at least un-
der certain nutritional conditions - lack of FASN 
may aggravate liver injury. Conversely, effective 
and complete lipogenesis e.g. conversion of 
acetyl-CoA and malonyl-CoA into palmitate, 
which can subsequently be esterified into 
triglycerides, prevents the potentially harmful 
increase of mitochondrial oxidation and ROS 
generation, since triglycerides themselves are 
not toxic but buffer the accumulation of fatty 
acids [7,34]. Therefore, FASN expression in 
steatotic hepatocytes may be considered as a 
compensatory adaptation at early stages of 
NAFLD or NASH development, respectively. 
However, upon overriding the capacity of this 
homeostatic response FASN expression and 
lipogenesis, respectively, can no longer prevent 
increased lipid peroxidation and progression to 
inflammation and fibrogenesis.  
 
Certainly, the regulation of hepatic lipogenesis 
is a highly coordinated process occurring on the 
transcriptional as well as post-transcriptional 
level. Further, despite the fact that FASN is con-
sidered as the key enzyme of hepatic lipogene-
sis, we did not assess whether all the lipogenic 
steps are coordinated affected. Still, our study 
revealed a clear correlation between hepatocel-
lular lipid accumulation and FASN expression, 
which seems to be impaired in NASH. Further 
studies are required to unravel, whether FASN 
expression may serve as a diagnostic marker or 
therapeutic target for the progression from sole 
steatosis to steatohepatitis in patients with 
NAFLD. 
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